Why the study?
Growing data highlights edoxaban use in clinical settings, prompting an overview of real-world evidence for stroke and systemic embolic event prevention in AF patients to address clinical decision-making concerns.
Does edoxaban prevent stroke and systemic embolic events safely in patients with atrial fibrillation in real-world settings?
Design
Review
Authors
Loading...
Edoxaban supports stroke prevention in non-valvular AF; reinforces its role as a convenient NOAC option in clinical practice.
Does edoxaban prevent stroke and systemic embolic events safely in patients with atrial fibrillation in real-world settings?
Real-world data consistently supports the efficacy and safety of edoxaban for stroke prevention in atrial fibrillation, aligning with pivotal trial results and showing favorable bleeding profiles compared to vitamin K antagonists.
Serkan Çay (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: